D. E. Shaw & Co., Inc. Viridian Therapeutics, Inc.\De Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 138,067 shares of VRDN stock, worth $2.73 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
138,067Holding current value
$2.73 Million% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding VRDN
# of Institutions
179Shares Held
76.8MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$94.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$87.5 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$76.8 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$74.2 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$68.2 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $789M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...